Apixaban

阿哌沙班

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameApixaban
Drug Alias NameApixabanum阿匹沙班艾吡沙班阿派沙班Eliquis +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFactor Xa inhibitors
TargetsCoagulation factor X
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Aortic valve diseasesIschemic Stroke +[49] 
Global Approved IndicationsIschemic StrokeThrombosisVenous Thromboembolism +[5] 
Approved Indications in ChinaThrombosisVenous Thromboembolism
Original Approved Country/TerritoryEU
Original Approved Date2011/05/18
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Dexa Medica GroupBristol Myers Squibb Srlcompany +[20] 
Inactive CompaniesStanford UniversityUniversity Of South FloridaUniversity Of Vermont +[11] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeSolid tumours +[34] 
Inactive IndicationsAortic valve diseasesThrombocytopeniaAnemia, Sickle Cell +[15] 

Other Information

ATC CodeB01AF02
Related LinksWikipediaDrugBankKEGG